CAMP4 Therapeutics (CAMP) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 8.2% versus a loss of 30.4%. CAMP4 Therapeutics is the larger company by market cap ($198.9 million vs $189.7 million), about 1.0 times the size. CAMP4 Therapeutics converts more of its revenue into profit, with a net margin of -2298.5% versus -4658.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | RNAC |
|---|---|---|
| Share price | $3.17 | $6.27 |
| Market cap | $198.93M | $189.70M |
| 1-day change | -8.12% | -4.71% |
| YTD return | -48.29% | -13.04% |
| 1-year return | +8.19% | -30.41% |
| 5-year return | — | -94.71% |
| EPS (TTM) | $-2.35 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.50M | $2.80M |
| Revenue growth (YoY) | +436.50% | -92.81% |
| Net income (latest FY) | $-80.40M | $-130.30M |
| Operating margin | -1502.43% | -5127.10% |
| Net margin | -2298.54% | -4658.63% |
| 52-week high | $7.75 | $11.00 |
| 52-week low | $2.88 | $5.60 |
| Distance from 52-week high | -59.10% | -43.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +233.44% | +437.00% |
| Average volume | 267.29K | 131.23K |
| Shares outstanding | 62.75M | 30.26M |
| Employees | 48 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed RNAC by 38.6 percentage points over the past year.
- CAMP4 Therapeutics is more profitable, keeping -2298.5 cents of every revenue dollar as net income versus -4658.6 cents for Cartesian Therapeutics.
- CAMP4 Therapeutics grew revenue faster in its latest fiscal year (+436.50% vs -92.81%).
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
CAMP vs RNAC FAQ
Which is bigger, CAMP4 Therapeutics or Cartesian Therapeutics?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $198.93M compared with $189.70M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, CAMP or RNAC?
CAMP returned +8.19% over the past 12 months, compared with -30.41% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.